Código QR (código de barras bidimensional)

PACIFIC-5: a phase III clinical trial of consolidation durvalumab in patients with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy

Abstract Background Consolidation durvalumab following no progression on concurrent chemoradiotherapy (cCRT) is standard of care for unresectable stage III non-small-cell lung cancer (NSCLC). However, in clinical practice many patients receive sequential CRT (sCRT). The PACIFIC-5 trial aimed to eval...

Fuld beskrivelse

Na minha lista:
Principais autores: Yi-Long Wu, Lin Wu, Nan Bi, Timucin Cil, Hong Ge, Zhengfei Zhu, Chih-Liang Wang, Wei Zhang, Dongqing Lv, E. Mingyan, Jianguo Sun, Yi Pan, Maciej Krzakowski, Mustafa Dikilitas, Mehmet Ali Nahit Sendur, Young-Chul Kim, Yanjiao Yang, Rui Mao, Biao Zhang, Luhua Wang
Format: Artigo
Sprog:Inglês
Udgivet: BMC 2025-12-01
Serier:Journal of Hematology & Oncology
Fag:
Non-small-cell lung cancer
Immunotherapy
Chemoradiotherapy
Clinical trial
Phase III
Durvalumab
Online adgang:https://doi.org/10.1186/s13045-025-01768-1
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker